# Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy

> **NCT03345134** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shaheen Alanee** · enrollment: 20 (estimated)

## Conditions studied

- High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma
- Endoscopic Surgical Procedure
- Transitional Epithelial Cells

## Interventions

- **DRUG:** MK-3475 and BCG

## Key facts

- **NCT ID:** NCT03345134
- **Lead sponsor:** Shaheen Alanee
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2017-11-30
- **Primary completion:** 2021-01-01
- **Final completion:** 2021-01-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2017-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03345134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03345134, "Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03345134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*